Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening

Assay and Drug Development Technologies

Volumn 12, Issue 9-10, 2014, Pages 514-526

  Vidugiriene, Jolanta ^a   Leippe, Donna ^a   Sobol, Mary ^a   Vidugiris, Gediminas ^a   Zhou, Wenhui ^b   Meisenheimer, Poncho ^b   Gautam, Prson ^c   Wennerberg, Krister ^c   Cali, James J ^a  

^a PROMEGA CORPORATION   (United States)

^b Promega Biosciences LLC   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DAPORINAD; DINUCLEOTIDE; ENTINOSTAT; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RALOXIFENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ACRYLAMIDE DERIVATIVE; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; PIPERIDINE DERIVATIVE;

ARTICLE; BIOLUMINESCENCE; CELL ASSAY; CELL LEVEL; CELL LYSATE; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIMIT OF DETECTION; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; ANTAGONISTS AND INHIBITORS; HEPG2 CELL LINE; JURKAT CELL LINE; LUMINESCENCE; OXIDATION REDUCTION REACTION; PROCEDURES; STANDARDS;

ACRYLAMIDES; HEP G2 CELLS; HUMANS; JURKAT CELLS; LUMINESCENT MEASUREMENTS; NADP; OXIDATION-REDUCTION; PIPERIDINES;

EID: 84918519836     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2014.605     Document Type: Article

References (41)

1. Nakamura M, Bhatnagar A, Sadoshima J: Overview of pyridine nucleotides review series. Circ Res 2012;111:604-610.
2. Oka S, Hsu C, Sadoshima J: Regulation of cell survival and death by pyridine nucleotides. Circ Res 2012;111:611-627.
3. Ussher J, Jaswal J, Lopaschuk G: Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ Res 2012;111:628-641.
4. Ying W: NAD + /NADH and NADP + /NADPH in cellular functions and cell death: regulation and biological consequences. Atioxid Redox Signal 2008;10:179-206.
5. Pollak N, Dolle C, Ziegler M: The power to reduce: pyridine nucleotides-small molecules with a multitude of functions. Biochem J 2007;402:205-218.
6. Cairns R, Harris I, Mak T: Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
7. Xia W, Wang Z, Wang Q, et al.: Roles of NAD/NADH and NADP/NADPH in cell death. Curr Pharm Des 2009;15:12-19.
8. Jiang F, Zhang Y, Dusting G: NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 2011;63:218-242.
9. Chiarugi A, Dolle C, Felici R, Ziegler M: The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 2012;12:741-752.
10. Houtkooper R, Canto C, Wander J, Auwerx J: The secret life of NAD + : an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010; 3:194-223.
11. Berger F, Ramirez-Hernandez MH, Ziegler M: The new life of a centenarian: signaling functions of nad(p). Trends Biochem Sci 2004;29:111-118.
12. Stein L, Imai S: The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol Metab 2012;23:420-428.
13. Grahnert A, Grahnert A, Klein C, Schilling E, Wehrhahn J, Hauschildt S: Review: NAD + : a modulator of immune functions. Innate Immun 2011;17: 212-233.
14. Mouchiroud L, Houtkooper R, Auwerx J: NAD + metabolism: A therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol 2013;48: 397-408.
15. Billard J, Dennison J, Briand J, et al.: Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab 2013;1:19.
16. VanderPorten E, Frick L, Turincio R, Thana P, LaMarr W, Liu Y: Label-free highthroughput assays to screen and characterize novel lactate dehydrogenase inhibitors. Anal Biochem 2013;441:115-122.
17. Jones A, Hirst J: A spectrophotometric coupled enzyme assay to measure the activity of succinate dehydrogenase. Anal Biochem 2013;442:19-23.
18. Smith B, Hallows W, Denu J: A continuous microplate assay for sirtuins and nicotinamide producing enzymes. Anal Biochem 2009;394:101-109.
19. Bird D, Yan L, Vrotsos K, et al.: Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. Cancer Res 2005;65:8766-8773.
20. Vergen J, Hecht C, Zholudeva L, et al.: Metabolic imaging using two-photon excited NADH intensity and fluorescence lifetime imaging. Microsc Micoranal 2012;18:761-770.
21. Zhao Y, Jin J, Hu Q, et al.: Genetically encoded fluorescent sensors for intracellular NADH detection. Cell Metab 2011;14:555-566.
22. Hung Y, Albeck J, Tantama M, Yellen G: Imaging cytosolic NADH-NAD redox state with a genetically encoded fluorescent biosensor. Cell Metab 2011;14: 545-554.
23. Lorenz M, El Azzouny M, Kennedy R, Burant C: Metabolome response to glucose in the b-cell line INS-1 832/13. J Biol Chem 2013;288:10923-10935.
24. Trammell S, Brenner C: Targeted, LCMS-based metabolomics for quantitative measurement of NAD metabolites. Comput Struct Biotechnol J 2013; 4:1-28.
25. Lowry O, Rock M, Schultz D, Passonneau J: Measurement of pyridine nucleotides by enzymatic cycling. J Biol Chem 1961;236:2746-2755.
26. Graeff R, Lee H: A novel cycling assay for cellular cADP-ribose with nanomolar sensitivity. Biochem J 2002;361:379-384.
27. Umemura K, Kimura H: Determination of oxidized and reduced nicotinamide adenine dinucleotide in cell monolayers using a single extraction procedure and a spectrophotometric assay. Anal Biochem 2005;338:131-135.
28. Zhang J, Chung T, Oldenburg K: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
29. Iversen PW, Beck B, Chen YF, et al.: HTS Assay Validation. 2012 May 1 [Updated 2012 Oct 1]. In: Sittampalam GS, Gal-Edd N, Arkin M, et al. (eds). Assay Guidance Manual [Internet]. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004. Available from: http://www.ncbi.nlm.nih.gov/books/NBK8378326.
30. Pemovska T, Kontro M, Yadav B, et al.: Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013;3:1416-1429.
31. Yadav B, Pemovska T, Szwajda A, et al.: Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep 2014;4: 5193.
32. Zhou W, Leippe D, Duellman S, et al.: Self-Immolative bioluminogenic quinone luciferins for NAD(P)H assays and reducing capacity-based cell viability assays. Chembiochem 2014;15:670-675.
33. Hasmann M, Schemainda I: FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-7442.
34. Garten A, Petzold S, Korner A, Imai S, Kiess W: Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2008; 20:130-138.
35. Tan B, Young A, Lu Z, et al.: Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. JBC 2013;288:3500-3511.
36. Fallah-Sichani M, Honarnejad S, Heiser LM, et al.: Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 2013; 9:708-714.
37. Zhao L, Kroenke C, Song J, et al.: Intracellular water-specific MR of microbeadadherent cells: the Hela cell intracellular water exchange lifetime. NMR Biomed 2008;21:159-164.
38. Karpac J, Jasper H: Metabolic homeostasis: HDACs take center stage. Cell 2011;145:497-499.
39. Ye J: Improving insulin sensitivity with HDAC inhibitor. Diabetes 2013;62:685-687.
40. Park S, Leung C, Cheng Y: ATP modulates poly(ADP-ribose) polymerase-1- facilitated topoisomerase I-linked DNA replication in the presence of camptothecin. Mol Pharmacol 2008;73:1829-1837.
41. Martins-Maciel ER, Campos LB, Salgueiro-Pagadigorria CL, et al.: Raloxifene affects fatty acid oxidation in livers from ovariectomized rats by acting as prooxidant agent. Toxicol Lett 2013;217:82-89.